Willow Review: A $199 NAD+ Price With No Ladder Under It

Most of the prices this site checks turn out to be something else wearing a per-month suffix — a first-month teaser, a twelve-month prepay, a tier floor across four products. Willow's $199 NAD+ injection is not one of those. We pulled it from the company's own onboarding API and re-confirmed it on the live product page: one price object, no ladder array, no three-, six- or twelve-month rungs anywhere in the funnel. Cancel anytime. In this category that is rare enough that it is the reason this review exists.

The other reason is a caveat that has to come almost as early. Willow sells no sermorelin, and no growth-hormone peptide of any kind. If you arrived here from the peptide side of this site, read the next section before anything else.

What Willow does not sell

Willow's catalogue is five products: an NAD+ injection, and compounded semaglutide and tirzepatide each in an injectable and a sublingual form. That is the whole list. We checked the obvious peptide routes on the company's own site and every one of them returns a 404 — sermorelin, CJC-1295, ipamorelin, tesamorelin and MK-677 do not exist here, and neither does glutathione, standalone B-12, methylene blue, BPC-157, TB-500, testosterone or any supplement.

So Willow is on this site as an adjacent NAD+ and GLP-1 option and nothing more. It is not on our sermorelin board and it never will be while that list holds, because answering "I want a growth-hormone peptide" with a weight-loss service is a product swap rather than an alternative. If you want to know what actually separates the two categories, what sermorelin costs per month covers the peptide side and our GLP-1 page covers the other.

The $199, and the two things attached to it

NAD+, injectable, subcutaneous, 50 mg — $199. Dispensed by a named pharmacy, which Willow states in its terms.

Two qualifiers travel with that number and both are the company's own words rather than our inference.

First, it is billed against a 28-day supply. The checkout says you receive a 28-day supply every month. Twenty-eight-day cycles mean thirteen fills a year, not twelve — so a year of NAD+ at $199 is about $2,587, not the $2,388 that a "/mo" figure implies. That is roughly one extra charge a year, and it is the single most common way a genuinely flat price still costs more than you budgeted.

Second, $199 is the price at 50 mg. Willow's FAQ says medication costs vary by dosage, and its terms say the fee may be increased by a dosage increase. So it is a flat rate at a dose, not a flat rate forever.

Its weight-loss line is priced separately and conventionally: compounded semaglutide $299 a month and tirzepatide $399, the same either way whether you take the injection or the sublingual tablet, with an anti-nausea add-on at $30.

The value story nobody advertises

Here is a detail worth more than the headline. Willow's NAD+ protocol runs three injections a week in the first month, then optionally drops to once a week afterwards. The price does not change when the frequency drops.

That is not a scandal and it is not hidden — it is simply the arithmetic nobody puts in a comparison table. From month two you are paying the same $199 for roughly a third of the injections. Whether that is fine depends on what the maintenance dose actually is, which the company does not publish, and it is the first question to ask at intake rather than after the second charge.

An additive, or a treatment?

Willow's public NAD+ page sells the product on cognition, energy and brain fog, standalone. Its own internal product copy describes the same product as "an NAD+ additive… during your GLP-1 treatment".

The funnel matches the second description more than the first: the NAD+ intake is a weight-loss questionnaire, asking BMI, GLP-1 history and diabetes status. To Willow's credit, it does not gate on the answers — we walked a normal-BMI profile with no weight goal through to the same $199 checkout, so the product genuinely is available standalone. But the shape of the thing tells you where it came from, and it is worth knowing that the company that sells it internally thinks of it as an accessory to a weight-loss programme.

Worth saying plainly for readers of this site: NAD+ is not a growth-hormone peptide and has no relationship to the sleep-architecture mechanism sermorelin works through. Nothing about a GHRH analogue's effect on slow-wave sleep transfers to it.

What Willow is unusually good at

Credit where it is earned, because on the disclosure axis Willow is at the top of this batch rather than the bottom:

• •Twenty-five-plus named physicians, each with their own bio page, under a named chief medical officer who is dual board-certified. That is the largest set of individually named practising physicians of any service in this module — a different axis from Found Health, which names the most senior advisers, and from Sesame Care, where you pick the individual clinician yourself. (No NPIs are published, so we have not verified any of them individually.)
• •Three dispensing pharmacies named in its terms — Red Rock Home Pharmacy (which dispenses the NAD+), Epiq Pharmacy and The Pharmacy Hub — rather than the usual "licensed US pharmacies". One caveat worth carrying: The Pharmacy Hub is the same dispensary, at the same Miami address, that Try Ageless and System Labs name on our sermorelin board. Three unrelated brands, one facility — so a named pharmacy tells you the supply chain is visible, not that it is independent.
• •A verifiable certification seal — we pulled the seal image and confirmed it is issued, against a control that correctly failed.
• •A real state list, pulled from its own onboarding API: 36 states enabled, 14 disabled. Note that the sign-up dropdown still renders all fifty as selectable, so check yours against the list rather than against what the form lets you pick.
• •Clean on the FDA warning-letter database. Willow, both its legal entities and all three of its named pharmacies returned nothing on record when we screened them on 8 August 2026, on a search validated against a known positive in the same pass¹.

The rest of the caveats

The medication is compounded and not FDA-approved, which Willow says itself. Cancellation requests must arrive two full calendar days before the next ship date. It is explicitly a women's brand — its terms frame the whole service around women's health services — even though the NAD+ page itself is gender-neutral. Its "4.9 out of 5 from 2,200-plus reviews" and "100,000-plus patients" claims sit on no third-party platform we could find. And the NAD+ page is in the site's own navigation but absent from its sitemap, which is a small thing that tends to mean a page nobody owns.

On the GLP-1 side, the evidence behind the molecules is genuinely strong — semaglutide and tirzepatide both have large randomised weight-loss trials behind them²³ — but those trials were run on the branded products, not on compounded copies, and that distinction is the whole of the compounded-GLP-1 question.

Bottom line

$199 a month for a 50 mg NAD+ injection, and it really is the month-to-month rate — no ladder, no teaser, no prepay, which after checking dozens of these is genuinely unusual. Set against it: billing runs on 28-day cycles, so a year is thirteen charges and about $2,587; the dose frequency drops after month one and the price does not; the company's own internal copy treats the product as a GLP-1 add-on; and it sells no sermorelin and no GH peptide at all, so for a reader of this site it is an adjacent option rather than a peptide one. The clinical transparency — named physicians, named pharmacies, a verifiable seal, a real state list — is the best in this group.